CCO Management Series
The Role of Integrase Inhibitors in HIV Management
Targeting Integrase: Mechanisms of Action and Mechanisms of Resistance to Integrase Inhibitors |
Module 1 of 3 |
|
|
|
Martin Markowitz, MD, discusses the role of the integrase enzyme in the HIV replication cycle and the development of resistance to integrase inhibitors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of the integrase enzyme in the HIV replication cycle
- Discuss the mechanism of action of the current integrase strand transfer inhibitors raltegravir and elvitegravir
- Summarize the findings regarding the development of resistance in clinical trials of elvitegravir and raltegravir
- Discuss issues relating to cross-resistance between the integrase inhibitors elvitegravir and raltegravir
|
Clinical Studies of Integrase Inhibitors: A Comprehensive Review |
Module 2 of 3 |
|
|
|
Martin Markowitz, MD, discusses recent data from clinical studies involving the use of the integrase inhibitors raltegravir and elvitegravir.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the results of proof-of-concept clinical trials concerning the use of the integrase inhibitors raltegravir and elvitegravir as monotherapy
- Describe the results of clinical trials involving the use of raltegravir and elvitegravir in combination therapy regimens in treatment-naive and treatment-experienced patients
- Discuss the role of additional active agents in the optimized background regimens of raltegravir- and elvitegravir-containing antiretroviral therapy regimens
|
From Bench to Bedside: The Clinical Role of Integrase Inhibitors |
Module 3 of 3 |
|
|
|
David A. Cooper, MD, DSc, discusses clinical data on the use of integrase inhibitors for the management of treatment-experienced and treatment-naive HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount data from clinical studies of the use of the integrase inhibitors raltegravir and elvitegravir
- Discuss the role of integrase inhibitors in the management of treatment-experienced patients
- Identify management strategies for antiretroviral-experienced patients who experience virologic failure
|
Interactive Case Challenges
Management of a Moderately Treatment-Experienced Male Using Novel Antiretroviral Agents
|
|
|
Andrew R. Zolopa, MD, discusses key issues in the management of a chronically infected patient with persistent viremia.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the factors to be considered in designing a fully active antiretroviral regimen for a treatment-experienced patient
- Identify the key interactions between novel antiretroviral agents and other antiretroviral agents
- Describe the role of tropism testing, including the limitations of tropism testing in developing an antiretroviral regimen
|
Management of a Virologically Suppressed Patient Experiencing Injection Site Reactions With His Current Regimen
|
|
|
Jonathan M. Schapiro, MD, discusses management issues in the case of a treatment-experienced male who is experiencing intolerable adverse effects from his successful regimen.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the current indications for recently approved novel antiretroviral agents
- Discuss key factors to be considered in managing a virologically suppressed patient who is experiencing intolerable adverse events
- Discuss key factors to be considered in determining viral susceptibility to new agents in switch regimens
|
Management of a Patient With Extensive Antiretroviral Experience and Persistent Low-Level Viremia
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, discusses issues in managing a clinically stable male patient who has not been able to achieve undetectable HIV-1 RNA
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the current indications for recently approved novel antiretroviral agents
- Discuss key factors to be considered in managing a treatment-experienced patient who is experiencing persistent low-level viremia
- Discuss the reasons for including at least 2 new fully active agents when switching a patient to a new antiretroviral regimen
|
CCO Slideset
The Role of Integrase Inhibitors in HIV Management
 |
|
Martin Markowitz, MD, presents findings on the function of integrase and the role of integrase inhibitors in the management of HIV disease.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.44 MB
|
Expert Viewpoints
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|